CorMedix (NASDAQ:CRMD) Stock Keeps “Outperform” Rating at Oppenheimer

CorMedix (NASDAQ:CRMD)‘s stock had its “outperform” rating reissued by research analysts at Oppenheimer in a report released on Friday, Benzinga reports. They presently have a $13.00 price target on the stock, down from their previous price target of $15.00. Oppenheimer‘s price objective would indicate a potential upside of 167.77% from the company’s current price.

Several other brokerages also recently commented on CRMD. UBS Group set a $19.00 target price on shares of CorMedix in a research note on Tuesday. Needham & Company LLC boosted their price target on shares of CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday. Royal Bank Of Canada lifted their price objective on shares of CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings downgraded shares of CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday. Finally, Citigroup reiterated a “market outperform” rating on shares of CorMedix in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.22.

CorMedix Stock Up 0.3%

Shares of CRMD traded up $0.01 during midday trading on Friday, reaching $4.86. 477,683 shares of the stock were exchanged, compared to its average volume of 1,614,163. The company has a market cap of $378.40 million, a price-to-earnings ratio of 2.27, a P/E/G ratio of 0.99 and a beta of 1.48. The company has a quick ratio of 2.36, a current ratio of 2.56 and a debt-to-equity ratio of 0.31. CorMedix has a 12-month low of $4.72 and a 12-month high of $13.02. The firm has a 50 day simple moving average of $7.25 and a 200-day simple moving average of $7.58.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $51.76 million. CorMedix had a return on equity of 40.52% and a net margin of 40.49%. Research analysts forecast that CorMedix will post 0.54 EPS for the current year.

Institutional Investors Weigh In On CorMedix

Large investors have recently made changes to their positions in the business. Gryphon Financial Partners LLC lifted its position in CorMedix by 6.3% during the first quarter. Gryphon Financial Partners LLC now owns 27,401 shares of the company’s stock valued at $186,000 after buying an additional 1,618 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in CorMedix by 13.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,222 shares of the company’s stock valued at $113,000 after acquiring an additional 1,736 shares during the period. HighTower Advisors LLC boosted its stake in CorMedix by 8.2% during the second quarter. HighTower Advisors LLC now owns 32,655 shares of the company’s stock worth $256,000 after acquiring an additional 2,476 shares in the last quarter. Sigma Planning Corp boosted its stake in CorMedix by 8.5% during the third quarter. Sigma Planning Corp now owns 32,142 shares of the company’s stock worth $247,000 after acquiring an additional 2,531 shares in the last quarter. Finally, Advisors Asset Management Inc. bought a new stake in CorMedix during the third quarter worth about $26,000. 34.18% of the stock is currently owned by institutional investors.

CorMedix News Summary

Investors following CRMD have been watching these news items:

• Positive Sentiment: Management expects the Heron assets to contribute $125 million–$150 million in pro forma 2027 revenue and targets $45 million–$60 million in annual synergies, offering a potential growth and cost-saving opportunity if realized. Heron revenue and synergy expectations
• Positive Sentiment: Analyst coverage included a reported price-target increase from RBC and a positive outlook from Needham, which may support sentiment. RBC price-target report Needham analyst report
• Negative Sentiment: The company posted a $14.7 million net loss; reported EPS of a $0.19 loss missed the cited consensus estimate of a $0.12 loss. This contrasts with a Zacks report showing a smaller loss on its measure, underscoring differences in earnings calculations. Zacks Q3 earnings report

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.